Actively Recruiting
Study of PF-08634404 Alone or with Chemotherapy in Adults with Early-Stage or Locally Advanced Non-Small Cell Lung Cancer
Led by Pfizer · Updated on 2026-10-08
120
Participants Needed
37
Research Sites
156 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a new medicine called PF-08634404 to understand how it works alone or with chemotherapy in adults with early-stage or locally advanced non-small cell lung cancer NSCLC. This study focuses on patients whose cancer may or may not be removable by surgery and includes three parts based on disease diagnosis and treatment history. The trial aims to assess the safety and effects of PF-08634404 in different treatment settings for this lung cancer type. Participants will be assigned to one of three groups Part A tests PF-08634404 combined with chemotherapy before surgery neoadjuvant therapy Part B tests PF-08634404 alone after surgery in patients who did not have a complete response to prior chemo-immunotherapy Part C tests PF-08634404 alone as an additional treatment after chemoradiotherapy in patients with unresectable disease. All treatments are given intravenously at clinical sites under medical supervision. Throughout the study, participants will have medical tests to monitor organ health and cancer status. Researchers will evaluate adverse events, surgical feasibility, tumor response rates, survival outcomes, and laboratory measures including tumor DNA levels. Follow-up assessments may continue up to five years to observe long-term effects. The study involves regular visits for treatment administration and safety monitoring over several months or years depending on the assigned treatment part.
CONDITIONS
Brief Title
Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
Research Team
P
Pfizer CT.gov Call Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here